Company Overview

Our mission is to improve the lives of people living with diabetes, obesity and other cardiometabolic diseases.

We are applying our proven proprietary technology platform, Arestat®, to develop a portfolio of superior, proprietary products that address areas of high unmet patient need in high value markets.

Our aim is to have multiple options to drive a step-change in company value for our shareholders.

 

Latest Documents

Clarivate report – Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies

3 August 2026

Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

30 July 2026

Investor presentation – June 2026

24 June 2026

Contact: ir@arecor.com